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Abstract
NLR (nucleotide-binding domain, leucine-rich repeat) proteins are intracellular regulators of host
defense and immunity. One NLR gene, NLRP12/Monarch-1, has emerged as an important inhibitor
of inflammatory gene expression in human myeloid cells. This is supported by genetic analysis
linking the loss of a functional NLRP12 protein to hereditary periodic fever. NLRP12 transcription
is diminished by specific TLR stimulation and myeloid cell maturation, consistent with its role as a
negative regulator of inflammation. The NLRP12 promoter contains a novel Blimp-1/PRDM1
binding site, and Blimp-1 reduces NLRP12 promoter activity, expression and histone 3 acetylation.
Blimp-1 associates with the endogenous NLRP12 promoter in a TLR-inducible manner and mediates
the down-regulation of NLRP12 expression by TLR agonists. As expected, the expression of
NLRP12 and Blimp-1 is inversely correlated. Analysis of Blimp-1-/- murine myeloid cells provides
physiologic evidence that Blimp-1 reduces NLRP12 gene expression during cell differentiation. This
demonstrates a novel role for Blimp-1 in the regulation of an NLR gene.
Introduction
The recognition of microbial components during host infection is a key step in activating the
innate immune response followed by the induction of inflammatory gene expression. Pattern-
recognition receptors exemplified by Toll-like receptors (TLRs) are key regulators in host
response to bacterial, viral and fungal components (1,2). Central to this response is the ability
to upregulate genes involved in host protection, innate and adaptive immune cell recruitment
and pathogen clearance. Although the TLR-mediated inflammatory response is critical for
providing immune defense against pathogens, dysfunctional responses may lead to both acute
and chronic inflammatory states manifested as sepsis, inflammation and autoimmunity (3).
Therefore, the intensity and duration of TLR responses must be tightly controlled.
In addition to TLR, recent research has focused on the discovery and characterization of a new
immune gene family, the NLR (nucleotide binding domain, leucine rich repeat containing) gene
family (4), also known as CATERPILLER, NOD-LRR, NACHT-LRR or NOD-like receptor
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(5-8). Mutations in several NLR genes have been associated with human disease states
including autoimmunity and inflammation. Members of the NLR gene family are involved in
regulating cellular activation after exposure to specific or multiple pathogen-derived products
(9). NOD2 mediates cellular responses to peptidoglycan derived muramyl dipeptide (MDP),
leading to activation of inflammatory cytokines and the release of antimicrobial peptides from
cytosolic granules (10-12). Nlrp1b/Nalp1b, regulates disease susceptibility of some murine
strains to anthrax lethal toxin (13). NLRC4/IPAF mediates caspase-1 and IL-1 processing in
response to the flagellin of Salmonella typhimurium and Legionella pneumophila (14-16).
Naip5 mediates host susceptibility to the intracellular pathogen Legionella pneumophila (17).
NLRP3/cryopyrin/NALP3 mediates caspase-1 and IL-1 processing in response to an array or
stimuli (18-21). The more recently described NLRX1 gene negatively regulates the intracellular
type I interferon signaling pathway in mitochondria (22). Taken together these data suggest
that the NLR genes are involved in regulating a variety of host defense processes.
The relevance of NLR genes is most apparently revealed by the genetic analysis of patients
suffering from immune and inflammatory disorders. Mutations in CIITA result in the
immunodeficiency Type II Bare Lymphocyte Syndrome (Group A) (23). NOD2 mutations are
associated with increased susceptibility to inflammatory Crohns’ disease, and to a
granulomatous disorder known as Blau syndrome (24-26). Hyperactive mutants of the
NLRP3 (CIAS1) gene predispose patients to a variety of autoinflammatory disorders classified
as cryopyrin-associated periodic syndrome (CAPS), which falls under the general classification
of hereditary periodic fever (HPF) (27-32). Mutations in NLRP1/NALP1 has been genetically
linked with vitiligo-associated autoimmune disease (33) while NLRP7/NALP7 has been
associated with hydatidiform mole (34). These studies underscore the contention that NLR
family members are important players in both the maintenance of normal immune responses
and the onset of inflammatory disorders.
We and others have identified an NLR family member Monarch-1/PYPAF7, recently renamed
NLRP12 (35-37). NLRP12 is expressed primarily by cells of the myeloid-monocytic lineage,
including monocytes, granulocytes and eosinophils in humans (36). Although it has been
suggested that some NLR proteins are involved in “sensing” microbial components, currently
there is no known ligand for NLR proteins in general, and NLRP12 in specific. In vitro studies
in human cells employing both gene transfection and small heteroduplex RNA (shRNA)-
mediated gene silencing suggest that NLRP12 functions as a negative regulator of TLR and
tumor-necrosis factor receptor (TNFR) induced NF-κB signaling in human cells. NLRP12
blocks IRAK-1 hyperphosphorylation/activation (37) and facilitates the degradation of NF-
κB inducing kinase (NIK) leading to reduced NF-κB activation (38). A recent study of patients
with the clinical manifestation of HPF but without mutations in several HPF-linked genes
revealed a new genetic link to NLRP12 (39). In contrast to the genetic linkage of NLRP3 and
CAPS wherein a variety of hyperactive, single nucleotide missense mutants have been found
in patients, the known disease-linked NLRP12 mutants are represented by a splicing variant
that caused an 11 residue insertion and truncation of the LRR region in one family, and a
nonsense mutation that truncated a portion of the NBD domain and all of the LRR region in a
second family (39). These truncated NLRP12 proteins failed to inhibit NF-κB activation,
supporting the conclusion that NLRP12 exhibits an inhibitory function.
In contrast to most innate immune genes, human NLRP12 expression is down-regulated after
activation of myeloid cells with either TLR2 or TLR4 agonists, M. tuberculosis, or exposure
of cells to TNFα or IFNγ (36,37). Based on our current understanding of the function of
NLRP12, we hypothesize that NLRP12 is present prior to immune stimulation to maintain a
quiescent phenotype, but during infection its expression is reduced to allow for a full
inflammatory response to occur. At the center of this hypothesis is the downregulation of
NLRP12 by TLR and during states of myeloid cell differentiation. However, the mechanism
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by which TLRs and myeloid cell differentiation processes regulate NLR gene expression is an
uncharted territory. In this work, we show that the transcriptional silencer, Blimp-1/PRDM1
is involved in the transcriptional repression of NLRP12 after TLR activation or after myeloid
cell differentiation.
Blimp-1 is a DNA binding factor that recruits histone deacetylases, histone lysine
methyltransferases, histone arginine methyltranserses and co-repressors to induce promoter
silencing (40-43). The role for Blimp-1 in regulating B cell differentiation into antibody-
producing plasma cells has received the most attention (44). However, the role of Blimp-1
extends significantly beyond B cell differentiation, as it also controls T cell homeostasis and
activation (45,46). Most relevant to this work, Blimp-1 expression is induced during
differentiation of myeloid cell lines, whereby it reduces c-myc expression and promotes the
upregulation of myeloid-monocytic markers, CD11b and CD11c (47).
In this report we identify Blimp-1 as a key regulator of TLR-mediated, and differentiation-
associated reduction of NLRP12 in human myeloid-monocytic cells. We propose that Blimp-1
is important in restricting NLRP12 expression, thereby modulating the extent by which
NLRP12 inhibits inflammatory signaling. These data provide a new linkage between Blimp-1
and the innate immune TLR and NLR pathways.
Materials and Methods
Mice
Prdm1F/F and prdm1F/- mice (48) were crossed with Rosa26ERCre/+ mice to generate controls
(Rosa26+/+prdm1F/F ) and experimental (Rosa26ERCre/+prdm1F/F) mice. Mice were injected
with 1.5ml of 10mg/ml tamoxifen in sunflower seed oil (0.5ml/day over three days) to induce
gene deletion 3 weeks prior to tissue harvest. Mice were housed in the barrier facility of
Columbia University (New York, New York). All experiments were approved by the
institutional animal care and use committee of Columbia University.
Reagents
LPS derived from Escherichia coli 011:B5 (Sigma-Aldrich) was used at a final concentration
of 100 ng/ml; phorbol myristate acetate (PMA) (Sigma-Aldrich) was used to differentiate cells
at a concentration of 50 ng/ml. Antibodies included anti-Flag M2 (Sigma); anti-p65
(Rockland); anti-Blimp-1 (AbCam), anti-acetylated-H3 (Upstate); mouse IgG (Upstate).
Tissue culture cells and conditions
HEK293T, undifferentiated HL-60 cells, undifferentiated U937 cells and primary adherent
blood cells were maintained as previously described (37) . All cells were grown at 37°C with
5% CO2. HL-60 cells were differentiated with 1.25% DMSO as described below. U927 cells
were stimulated with 100 ng/ml LPS or differentiated with 50 ng/ml PMA.
Primary cell isolation and stimulation
Human granulocytes were isolated from buffy coats (American Red Cross) using the
Lymphocyte Separation Media (ICN, Costa Mesa, CA). For adherent cell purification, cells
were plated and allowed to adhere for 2 hours at 37°C. After three washes with PBS to remove
non-adherent cells, adherent cells were stimulated for the indicated time points with 100 ng/
ml LPS from Escherichia coli (LPS 011:B5; Sigma-Aldrich), or where indicated 100 ng/ml
K12 LPS, 0.1 μg/ml Pam3Cys, 1 × 108 cells/ml HKLM or 1 μg/ml Flagellin (Invivogen).
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Isolation and differentiation of murine bone marrow cells
Bone marrow cells from either wild-type C57BL/6N or treated /Rosa26//^ERCre/+ prdm1//
^flox/flox/ and /Rosa26//^+/+ prdm1^flox/flox / mice were flushed from the tibiae and femurs
and cultured at 1 × 106 cells/ml in MEM medium supplemented with 5% GM-CSF [culture
supernatant from X63 cells transfected with murine GM-CSF cDNA (provided by Dr. Chris
Nicchitta, Duke University, Durham, NC)]. Total cells (adherent and non-adherent) were
isolated at the indicated time points and RNA was prepared using Trizol Reagent (Invitrogen)
and analyzed for NLRP12 expression by qPCR.
Expression plasmids
The Flag-tagged Blimp-1 expression vector was previously described (49). A sequence
containing 1158 bp of the NLRP12 promoter was cloned into pGL3-Basic (Promega) luciferase
reporter vector and called Mon-1 luc. Site directed mutagenesis was used to mutate four base
pairs of the Blimp-1 binding site in using the QuikChange Site Directed Mutagenesis Kit
(Stratagene). Primers were NLRP12 5′-
GGAAGAGACAGCAGACTCGAGAATCTTTTTCATC-3′ and 5′-
GATGAAAAAGATTCTCCTCTCTGCTGTCTCTTCC-3′. To generate the pGL4.10 based
luciferase vectors the following Forward primer sequences were used, each containing KPNI
sites for cloning: pGL4-1412; 5′- GCGGTACCGAGAATTAGCCAGGCGTGTTG -3′;
pGL4-852 5′- GCGGTACCGCATGGTGGCGCATGTCTGTGGT -3′; pGL4-399 5′-
GCGGTACCCTGGAAGAGGCGCAGTCGCAGTT -3′; a common reverse primer was used
for all PCR reactions and contains a HindIII site for cloning 5′-
GCGAAGCTTCCTGGAGGCTGAGATGCTCCTATG -3′.
Identification of a potential Blimp-1 binding site in the NLRP12 promoter
The NCBI and Transcription Element Search Software (TESS)
(http://agave.humgen.upenn.edu/utess/tess) databases were used to search for potential
transcription factor binding sites within the NLRP12 promoter.
Luciferase Reporter Gene Assays
For transfections, 1×106 U937 cells were transfected with AMAXA nucleofector (AMAXA)
with 0.2 μg phRL-luc, 0.5 μg of NF-κB luc, Mon-1 luc or mutMon-1 luc. Where indicated,
cells were transfected with 1.0 μg of Flag-Blimp-1 or stimulated with LPS. Firefly luciferase
values were normalized to Renilla luciferase control values when harvested 24 h post-
transfection.
EMSA
HEK293T cells were transfected with pcDNA3 or a Flag-tagged Blimp-1 using Fugene 6.
EMSA was performed as previously described (50). For supershifts, 1 μl of anti-Flag M2
antibody (Sigma) or anti-p65 antibody (Rockland) was added and the binding reaction was
allowed to proceed for an additional 15 min. Protein-DNA complexes were resolved on a non-
denaturing polyacrylamide gel. Oligo pairs were annealed in STE buffer (10 mM Tris pH 8.0,
50 mM NaCl, 1mM EDTA) and T4 kinase-labeled with [α-32p] CTP. Primers used for NLRP12
EMSA were 5′- GGAAGAGACAGCAGAAGTGAAAATCTTTTTCATC-3′ and 5′-
GATGAAAAAGATTTTCACTTCTGCTGTCTCTTCC-3′. The consensus Blimp-1 binding
site is underlined.
DNA affinity purification assays
DAPA experiments were performed using the μMACS Streptavidin Kit (Miltenyi Biotec).
Briefly, 1 μg of 5′-biotinylated, duplexed oligo corresponding to the Blimp-1 binding site in
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the NLRP12 promoter (shown above for EMSA) was coupled to streptavidin beads for 30 min
at 4°C followed by addition of nuclear extract (500 ng) for 30 min. DNA—protein complexes
were immobilized magnetically and washed four times with 20 mM HEPES—KOH pH 7.9,
100 mM KCl and 2.5 mM MgCl2. Specifically bound proteins were eluted with 20 mM HEPES
—KOH pH 7.9 and 1 M NaCl. Eluates were electrophoresed on denaturing polyacrylamide
gels for subsequent immunoblot analysis using anti-Blimp-1.
Chromatin immunoprecipitation assays
ChIP analysis was performed as previously described (51) with some modifications. Briefly,
protein—DNA complexes were crosslinked with for 10 min with formaldehyde and cells were
harvested. Cells were either snap-frozen in dry ice/EtOH and stored at −80°C or immediately
used. DNA in lysed cells was sonicated to lengths of 500–1000 bp and anti-Blimp-1 (AbCam),
anti-acetylated-H3 (Upstate) or mouse IgG (Upstate) was used for immunoprecipitation
overnight at 4°C. SYBR Green quantitative qPCR was performed and values were expressed
as a percent of total input DNA for each time point. Primers to amplify the NLRP12 promoter
were: 5′- CCTGGAAGAGGCGCAGTCGCAGTT-3′ (forward) and 5′-
CCGAGGAGCCACTTGGCTGATGAA-3′ (reverse). For visualization, PCR fragments from
the ChIP analysis were run on an agarose gel.
Immunoprecipitation and Western analysis
The U937 cell line was stimulated with 100 ng/ml LPS or 50 ng/ml PMA for the indicated
time. Cells were lysed in lysis buffer (50mM Tris-HCl pH 8.0, 150 mM NaCl, 1% NP-40)
supplemented with Complete protease inhibitor cocktail (Roche). Protein concentrations were
determined by Bradford assay (BioRad) and equivalent amounts of cellular extract were used
in subsequent immunoprecipitations using rabbit polyclonal antisera against human NLRP12
as described with polyclonal goat anti-Blimp-1 (AbCam) or mouse monoclonal anti-GAPDH
(Chemicon). Immunoblots were visualized by enhanced chemiluminescence (Pierce).
Measurement of NLRP12 mRNA Stability
Nuclear versus cytoplasmic transcripts were isolated using the PARIS Kit following the
manufacturers protocol (Ambion), and qPCR was performed with primers recognizing process
mRNA. Measurement of DRB regulated mRNA stability was performed as previously
described (52). HL-60 cells were treated with 1.25% DMSO for 4 days to induce differentiation
to neutrophils and expression of NLRP12. Cells were replated and stimulated with LPS,
exposed to 50 μM 5,6-dichloro-1-ß-ribofuranosyl benzamidazole (DRB; Sigma-Aldrich)
dissolved in 0.1% DMSO, or exposed to 0.1% DMSO as a vehicle control. NLRP12 expression
was quantified by qPCR and normalized to the housekeeping gene GusB expression levels.
RNA Preparation and QPCR
Total RNA was isolated according using Trizol reagent (Invitrogen). qPCR results are
normalized to 18S r RNA or GUSB mRNA internal controls and are expressed in relative
numbers. Primers were: Human NLRP12 F 5′-AGAGGACCTGGTGAGGGATAC-3′, R 5′-
CTTCCAGAAGGCATGTTGAC-3′, probe 5′- CCCGTCCTCACTTGGGAACCA-3′. 18S F
5′-GCTGCTGGCACCAGACTT-3′, R 5′-CGGCTACCACATCCAAGG-3′, probe 5′-
CAAATTACCCACTCCCGACCCG-3′. GUSB (ABI: Hs99999908_m1). Mouse NLRP12 F
5′-CGACCCACCAGAACCTTCAG -3′, R 5′-CAGGCAGCATGTTCCTTTCC -3′, probe 5′-
TCCAGACTCAGTCCACATACTTAC-3′.
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NLRP12 expression is regulated by specific TLRs
NLRP12 is expressed by cells of the myeloid and monocytic lineage (35,37). Myeloid and
monocytic cells are involved in the innate immune response to pathogens, and recognize
invading microorganisms via Toll-like receptors (TLRs) on their cell surface (53). We have
recently shown that NLRP12 is a negative regulator of TLR1/2 and TLR4 signaling in human
monocytic-macrophage cell lines, and that ablation of NLRP12 increases pro-inflammatory
gene expression (37). Moreover, NLRP12 inhibits CD40-mediated NF-κB activation by
promoting the protein degradation of NF-κB inducing kinase (NIK) (38). NLRP12 mRNA
expression is reduced within one hour of TLR1/2, TLR4 or microbial pathogen stimulation
(37) and to a lesser extent after exposure of cells to TNFα or  (36). To determine if
NLRP12 expression is regulated by other TLR agonists, we exposed primary human
granulocytes for 1 hour to Heat Killed Listeria monocytogenes (HKLM) (TLR2), the synthetic
analog of double stranded RNA (PolyI:C) (TLR3), E. Coli K12 rough LPS (TLR4), and S.
thyphimurium flagellin (flagellin) (TLR5) (Figure 1A). Pam3Cys4 (TLR1/2) was used as a
control as we have previously observed that NLRP12 expression is down-regulated in response
to stimulation with this agonist. NLRP12 mRNA expression was dramatically reduced after
exposure of granulocytes to Pam3Cys4, HKLM and K12 LPS, but not in response to
stimulation with poly I:C or flagellin, although these cells were determined to express and be
responsive to TLR3 and TLR5 stimulation (Figure 1A and Figure 1B). Functional TLR3 and
TLR5 receptors have been previously observed in granulocytes (54,55). The observation that
NLRP12 expression was not altered to the same extent in response to each TLR agoinst suggests
that down-regulation of NLRP12 is mediated by specific TLRs.
To assess the kinetics of NLRP12 down-regulation by TLR stimulation, human primary
adherent peripheral blood mononuclear cells (PBMC) were isolated and exposed to purified
lipopolysaccaride (LPS) from E. coli which activates TLR4 (Figure 1C). NLRP12 expression
is down-regulated 1 hr after TLR stimulation, and it remained low 6 hours, 8 hours and 16
hours post-stimulation. This indicates the sustained down-regulation of NLRP12 in primary
human myeloid cells via TLR.
TLR stimulation affects NLRP12 mRNA transcription
The sustained decrease in NLRP12 expression following TLR stimulation led us to examine
whether NLRP12 is regulated at the level of mRNA stability, transcription, or both. We first
examined the transcription rate of the NLRP12 gene by comparing nuclear and cytoplasmic
NLRP12 mRNA levels after exposure of U937 cells to LPS (Figure 1D). This approach has
been proven as a sensitive and reliable method often used as an alternative to a nuclear run-on
assay (52). U937 cells were stimulated for the indicated time points with LPS followed by
separate isolation of nuclear and cytoplasmic mRNA followed by qPCR analysis of NLRP12
transcripts. The levels of NLRP12 mRNA were similar in both the nuclear and cytoplasmic
compartments, suggesting that the reduction of NLRP12 mRNA caused by TLR signaling is
partly or primarily attributed to an effect on transcription. As an alternative measure of mRNA
stability, we used 5,6-dichlororibofuranosyl benzimidazole (DRB) to chemically block gene
transcription in the HL-60 cell line. The human monocyte HL-60 cell line was treated with
DMSO for three days to promote granulocyte differentiation and NLRP12 expression. It was
necessary to use the HL-60 cell line as addition of DMSO to the U937 cell line promotes
differentiation induced down-regulation of NLRP12 (K.L. Williams, unpublished
observations). Differentiated HL-60 neutrophils were then analyzed for the level of NLRP12
transcripts after TLR stimulation, blocking transcription with DRB in DMSO, with both LPS
and DRB, or with DMSO alone (Figure 1E). NLRP12 mRNA was relatively stable in the
untreated control cells, however its level was reduced in cells treated with the transcriptional
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inhibitor DRB or with LPS alone. The reduction with these two treatments is not statistically
different as assessed by a Students t test (p=0.17). The inclusion of both DRB and LPS did not
cause an additive effect. Taken together, these results suggest that the decline in NLRP12
mRNA is significantly altered by the transcriptional inhibitor DRB, and that the reduction of
NLRP12 mRNA caused by TLR signaling is attributed to an effect on transcription.
The NLRP12 promoter contains a potential novel Blimp-1 binding site
Our data thus far suggest that the down-regulation of NLRP12 mRNA after TLR stimulation
involves transcriptional regulation. To identify potential factors involved in down-regulating
NLRP12, we analyzed the first 622 bp sequence of the NLRP12 promoter for transcription
factor-binding sites using the Transcription Element Search Software (TESS)
(http://agave.humgen.upenn.edu/utess/tess). We identified several transcription factor binding
sites including PU.1, which is involved in myeloid cell activation and differentiation (56)
(Figure 2A). Sequence analysis also revealed a potential binding site for Blimp-1 encoded by
the gene, PRDM1 located at nucleotide position -80 relative to the transcription start site (Figure
2A) (57). All previously identified Blimp-1 binding sites contain the consensus sequence
(A/C)AG(T/C)GAAAG(T/C)(G/T) with the exception of the NLR gene CIITA which contains
the sequence (A/C)AG(T/C)GAAAT(T/C)(G/T) (49,57,58). Analysis of the putative Blimp-1
binding site in NLRP12 suggests that this site contains the sequence (A/C)AG(T/C)GAAAA
(T/C)(C), which is different from the previously identified consensus sequence (Figure 2B).
NLRP12 and Blimp-1 protein expression are inversely correlated during TLR stimulation and
myeloid cell differentiation
The identification of a potentially novel Blimp-1 binding site in the NLRP12 promoter led us
to question whether Blimp-1 is important for the silencing of NLRP12 expression. We
hypothesized that NLRP12 expression might be down-regulated by an increased level of
Blimp-1 protein expression after TLR stimulation and cell differentiation. To assess this, we
first examined the expression of NLRP12 and Blimp-1 proteins in the monocyte cell line U937
after stimulation with LPS for 0, 2, 4, 8 and 24 hours (Figure 2C, top panel). We observed a
rapid down-regulation of NLRP12 protein expression with little NLRP12 protein detectable
at 2 hours after LPS stimulation. In contrast, Blimp-1 protein expression was increased at 2-4
hrs after TLR stimulation, and this increase continued at 8 and 24 hours after TLR activation
(Figure 2C, bottom panel). Immunoblots were probed with anti-GAPDH to indicate equal
loading. While the data suggest that NLRP12 and Blimp-1 protein expression are inversely
correlated, we initially observed a delay in Blimp-1 protein induction at the 2 hour time point.
Our data suggest that in addition to Blimp-1 it is possible that other transcription factors are
involved in the LPS mediated down-regulation of NLRP12. In addition to the Blimp-1 binding
site in the NLRP12 promoter, we observed several binding sites for PU.1. PU.1 is a positive
regulator of gene transcription and is expressed in monocyte cells (59). More importantly, PU.
1 is down-regulated by LPS (60), which may also attribute to the rapid reduction in NLRP12
protein after LPS stimulation. These data suggest that the inhibitory effect of TLR4 activation
on NLRP12 protein expression is, in part, inversely correlated with its effect on Blimp-1 protein
expression.
Blimp-1 mediates cell differentiation in several cell types including myeloid cells, and its
expression is increased during myeloid-monocytic differentiation (45-48,61-64). Thus, we
examined if NLRP12 expression might also be inversely correlated with Blimp-1 during
myeloid differentiation. To test this, the U937 cell line was treated with PMA for 0, 2, 4, 8 and
24 hours to induce cell differentiation followed by analysis of NLRP12 and Blimp-1 protein
expression (Figure 2D). NLRP12 protein expression was down-regulated beginning at two
hours after PMA-induced differentiation and expression disappeared by 4 hours (Figure 2D,
top panel). Conversely, the induction of Blimp-1 protein expression after PMA stimulation
Lord et al. Page 7













began four hours after PMA addition (Figure 2D, middle panel). Immunoblots were probed
with anti-GAPDH to indicate equal loading. These results show that the decrease of NLRP12
during differentiation correlates with an increase in Blimp-1 protein expression. These data
led us to hypothesize that the induction of Blimp-1 expression during TLR stimulation and cell
differentiation might be one mechanism by which NLRP12 expression is down-regulated.
Blimp-1 binds to the NLRP12 promoter after TLR stimulation and differentiation
To address the potential role for Blimp-1 in regulating NLRP12 gene expression, we assessed
if Blimp-1 could bind to the NLRP12 promoter. Electrophoretic Mobility Shift Assay (EMSA)
was performed using a 30 bp oligonucleotide containing the putative Blimp-1 binding sequence
5′-AAGTGAAAATC-3′ in the NLRP12 promoter. Nuclear extracts were prepared from
HEK293T cells transfected with a pcDNA3 control vector or Flag-tagged Blimp-1. EMSA
revealed a DNA-protein complex in the lane containing Flag-Blimp-1 but not in the pcDNA3
vector control lane (Figure 3A, left panel, lanes 3 and 2 respectively). This complex was
competed by increasing amounts of cold competitive probe indicating specificity (Figure 3A,
left panel, lanes 4 and 5). Addition of a Flag antibody to the binding reaction resulted in a
slower migrating band, indicating the presence of Flag-Blimp-1 in the DNA-protein complex
(Figure 3A, lane 6). This complex was not shifted by a control anti-p65 antibody indicating
specificity of antibody binding (Figure 3A, lane 7). These data show that Blimp-1 can bind to
the novel Blimp-1 binding site found on the NLRP12 promoter.
We next used DNA affinity purification assays (DAPA) to test the binding of Blimp-1 to the
NLRP12 promoter to assess if increased binding could be observed after TLR stimulation or
cell differentiation. We stimulated the U937 monocyte cell line with LPS or differentiated them
with PMA for 24 hours and performed DAPA analysis (Figure 3B). Nuclear extracts from
control unstimulated U937 cells and LPS stimulated or PMA treated U937 cells were incubated
with double-stranded biotinylated oligonucleotides containing the putative Blimp-1 binding
site in the NLRP12 promoter. Bound proteins were eluted followed by immunoblotting with
an antibody to Blimp-1. A dramatic increase in Blimp-1 signal was observed after cells were
stimulated with PMA or LPS. These results indicate that Blimp-1 in myeloid cells can bind to
the NLRP12 promoter, and that this binding is increased after TLR activation by LPS or cell
differentiation with PMA.
NLRP12 expression is down-regulated by Blimp-1
The observation that Blimp-1 binds to a novel site on the NLRP12 promoter in vitro supports
the idea that Blimp-1 mediates the repression of NLRP12 expression in vivo. To test this, we
generated a luciferase reporter vector driven by 1412 bp of the NLRP12 promoter (NLRP12-
luc) as well as a NLRP12-luc vector in which the Blimp-1 binding site was mutated
(mutNLRP12-luc) (Figure 4A). The pGL3-Control vector served as a positive control for
transfection efficiency. The U937 cell line was transfected with NLRP12-luc, mutNLRP12-
luc or pGL3-Control luciferase reporter vectors, and either co-transfected with Flag-Blimp-1
or stimulated with LPS (Figure 4B). We observed a similar decrease in luciferase activity in
cells containing the NLRP12-luc reporter vector when stimulated with LPS or when co-
transfected with Flag-Blimp-1. This is comparable to the extent that Blimp-1 reduces the pIV
promoter of CIITA and to which Bach2 represses the Blimp-1/Prdm1 gene in promoter reporter
assays (65, 66). Neither LPS nor Blimp-1 affected the mutNLRP12-luc vector that contained
a mutated Blimp-1 site, indicating that the Blimp-1 binding site in the NLRP12 promoter is
required for LPS or Blimp-1 mediated down-regulation of NLRP12. As a control, cells were
transfected with a pGL3-Control vector, which contains SV40 promoter driven luciferase
activity. When stimulated with LPS, pGL3-Control cells had a higher level of luciferase
reporter activity, supporting previous data that SV40 promoter activity is up-regulated by LPS
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stimulation (67). When co-transfected with Blimp-1, we did not observe a difference in pGL3-
Control reporter activity relative to control cells.
In order to confirm these results, we also cloned shorter regions of the NLRP12 promoter and
the full length 1412 bp fragment into the pGL4.10 luciferase vector. The pGL4.10 luciferase
vector was chosen due to the improved levels of signal to noise ratio as compared to the older
pGL3 luciferase version (Figure 4A). The U937 cell line was transfected with NLRP12-luc,
pGL3-Control, pGL4.10 vector, pGL4 containing 399 bp of the NLRP12 promoter
(pGL4-399), pGL4 containing 852 bp of the NLRP12 promoter (pGL4-852) and pGL4
containing 1412 bp of the NLRP12 promoter (pGL4-1412) luciferase reporter vectors. Cells
were either co-transfected with Flag-Blimp-1 or stimulated with LPS (Figure 4C). Consistent
with our previous observations, we observed a decrease in luciferase activity in cells containing
all of the NLRP12 reporter vectors when stimulated with LPS or when co-transfected with
Flag-Blimp-1. A Students T Test was used to determine significance where indicated. Taken
together, these data suggest that the NLRP12 promoter is regulated by Blimp-1, and that a
functional Blimp-1 binding site is necessary for LPS or Blimp-1 mediated down-regulation of
NLRP12 promoter.
TLR stimulation induces Blimp-1 binding to the NLRP12 promoter in vivo
Our observations suggested that Blimp-1 binds the NLRP12 promoter in vitro as assessed by
EMSA and DAPA analysis, and that Blimp-1 can repress an NLRP12 promoter luciferase
reporter construct. To determine if Blimp-1 binds to the NLRP12 promoter in vivo in an LPS
induced manner, we performed chromatin immunoprecipitation assays (ChIP). U937 cells
were stimulated with LPS for 8 hours followed by immunoprecipitation of protein-DNA
complexes with anti-IgG or with anti-Blimp-1. PCR using NLRP12 promoter specific primers
which result in a 300 bp product surrounding the Blimp-1 site was performed on input DNA,
a 1/10 dilution of input DNA, and ChIP performed with anti-IgG or anti-Blimp-1 antibodies
followed by visualization by gel electrophoresis (Figure 5A). Samples precipitated with the
anti-Blimp-1 antibody show that endogenous Blimp-1 is recruited to the NLRP12 promoter in
vivo after TLR stimulation. To assess the kinetics of Blimp-1 binding we then stimulated U937
cells for 0, 4 and 8 hours followed by ChIP with anti-IgG or anti-Blimp-1 antibodies as
described above (Figure 5B). Blimp-1 association with the endogenous NLRP12 promoter
increased by two-fold 4 hours after LPS stimulation, and six-fold by 8 hours. Primers specific
for the NQO1 promoter which is not regulated by Blimp-1 were used as a negative control
(Figure 5B). These data suggest that Blimp-1 associates with the NLRP12 promoter in an LPS
induced manner.
Transcriptional silencing is often associated with decreased histone acetylation. Blimp-1
recruits the G9a methyltransferase, and confers transcriptional silencing by inducing histone
H3 acetylation and methylation (42). To assess if the binding of Blimp-1 to the NLRP12
promoter is correlated with a decrease in H3 acetylation, we stimulated U937 cells for 0, 4 and
8 hours followed by ChIP with anti-IgG or anti-acetylated Histone 3 antibodies. We observed
that acetylated-Histone 3 levels were reduced by four-fold at the four and eight hour time point,
suggesting that the NLRP12 promoter is being transcriptionally silenced (Figure 5C). These
data show that LPS reduced transcriptional activity of the NLRP12 promoter is characterized
by decreased histone acetylation and increased association of Blimp-1.
Endogenous Nlrp12 gene expression is regulated by Blimp-1 in primary cells
The observation that NLRP12 and Blimp-1 protein expression is inversely correlated in human
myeloid cells during LPS stimulation and differentiation led us to examine the expression of
these two genes in primary myeloid cells from mice. However, we have not observed decreased
Nlrp12 expression upon LPS stimulation of mouse bone marrow cells, likely reflecting species-
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variation in the regulation of this gene. Thus we concentrated on Nlrp12 expression during
myeloid differentiation. In vitro differentiation of murine bone marrow with GM-CSF induces
the differentiation of hematopoietic progenitors into more mature dendritic cells and
macrophages. To determine if NLRP12 and Blimp-1 expression is altered during differentiation
of mouse bone marrow cells, we isolated bone marrow from C57BL/6 mice and differentiated
these cells in vitro for a period of five days with GM-CSF. We observed a decrease in
NLRP12 expression over the GM-CSF differentiation period as assessed by qPCR but not by
LPS stimulation of murine cells as expected (Figure 6A). Conversely, Blimp-1 expression was
increased during the differentiation period. Thus, NLRP12 and Blimp-1 expression are
inversely correlated during differentiation of murine bone marrow cells with GM-CSF in
vitro.
Next, we determined whether Blimp-1 mediates the transcriptional repression of NLRP12
during murine bone marrow differentiation. We obtained cells from Rosa26ERCre/+prdm1F/F
Cre-lox mice made from the Rosa26 ES cell line which ubiquitously expresses lacZ in adult
mouse tissues as described previously (68). For our studies, Blimp-1 null bone marrow cells
were obtained from Rosa26ERCre/+prdm1F/F mice following treatment of the mice with
tamoxifen to activate the Cre recombinase resulting in deletion of the Blimp-1 gene (68).
Isolated Blimp-1-deficient bone marrow cells were differentiated in vitro with GM-CSF for
the indicated time points (Figure 6B). GM-CSF caused a steady decrease in NLRP12 expression
over a period of 5 days as shown in the control Blimp-1 expressing cells from
Rosa26+/+prdm1F/F mice, although the data did not reach statistical significance. From days
1-4 of GM-CSF treatment, NLRP12 was reduced in the Blimp-1-deficient
Rosa26ERCre/+prdm1F/F cells but to a much lesser extent relative to the control Blimp-1
expressing Rosa26+/+prdm1F/F cells. By day 5, expression was reduced in both cell types
regardless of the presence of Blimp-1 (Figure 6B). It may by possible that additional
transcription factors including PU.1 are also involved. The data indicate that Blimp-1 reduces
NLRP12 during the early points of GM-CSF stimulation but its expression is reduced by
additional mechanism(s) after prolonged GM-CSF stimulation. Thus, inhibition of NLRP12
expression observed during differentiation of murine bone marrow cells is mediated in part by
Blimp-1.
Discussion
Based on in vitro analysis as well as the analysis of patients with NLRP12 splicing or nonsense
mutations, this gene has emerged as a negative regulator of inflammatory gene induction.
NLRP12 modulates TLR inflammatory gene induction by its inhibition of IRAK-1
hyperphosphorylation (37) and NIK activation (38). The negative regulatory functions of
NLRP12 have been shown to require ATP binding (69). In human myeloid cells, NLRP12
expression is down-regulated both by cellular activation through TLR stimulation as well as
developmentally after exposure of myeloid cells to TNFα and IFNγ (36). While NLRP12 is
expressed in monocytes, it is not expressed in differentiated macrophages suggesting that the
regulation of NLRP12 is under developmental control (35-37). Thus, the differentiation of
monocytes into macrophages, and the inflammatory response after TLR stimulation involves
the repression of NLRP12.
The observation that NLRP12 expression is down-regulated after TLR mediated activation of
human myeloid cells and by myeloid differentiation of monocytes to macrophages is unusual
for most innate immune genes. More often, proteins which function as negative regulators of
TLR signaling are induced after activation and are thought to inhibit the signaling pathways.
An example of TLR induced expression of negative regulators includes but the induction of
IRAK-M (70)as well as the induction of A20 (71) which are both induced 2-3 hours after LPS
exposure and “turn off” downstream activation by associating with TLR pathway signaling
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proteins to once expressed. Based on our current understanding of the function of NLRP12 we
hypothesize that NLRP12 is present prior to immune stimulation to maintain a quiescent
phenotype by inhibiting inappropriate TLR activation in the absence of appropriate signals.
We further hypothesize that during states of infection NLRP12 initially functions to modulate
over-zealous immune responses by associating with and regulating the activity of TLR
signaling proteins including IRAK-1 and NIK (37,38). Since we have observed that NLRP12
regulates both TLR and TNFR pathways, we hypothesize that at later time points after TLR
activation or during states of myeloid differentiation NLRP12 expression is decreased in order
to allow a more complete immune response to occur. The hypothesis that NLRP12 initially
functions to modulate over-zealous immune responses is supported by the recent observation
that humans with mutations in NLRP12 are predisposed to the autoimmune syndrome known
as hereditary periodic fever (39). Future characterization of the function of NLRP12 will likely
lead to a greater understanding of the role of NLRP12 down-regulating after TLR activation
and myeloid differentiation.
This report shows that Blimp-1 represses the NLRP12 promoter in transformed and primary
myeloid-monocytic cells. This is mediated by the binding of Blimp-1 to the NLRP12 promoter
in intact cells resulting in a correlative loss of histone acetylation. The regulation of NLRP12
gene expression by Blimp-1 is most convincingly shown using a Blimp-1 Cre-knockout mouse
where the down-regulation of NLRP12 during GM-CSF-dependent differentiation of bone
marrow progenitors is lessened in Blimp-1-/- cells. These data indicate that Blimp-1 reduces
NLRP12 expression during cell differentiation and TLR signaling.
Blimp-1 has long been implicated as a master regulator of B cell differentiation into plasma
cells (72,73). It is expressed in antibody-secreting plasma cells and plasmablasts, is required
for the formation of immunoglobulin secreting plasma cells (48,61) and is induced after TLR
activation in B cells (74). Most relevant to this work, Blimp-1 is induced during differentiation
of myeloid cell lines, whereby it promotes the induction of macrophage cell morphology
(47). Here we confirm that increased Blimp-1 causes the reduction of NLRP12 expression
during TLR-mediated activation and PMA-mediated differentiation.
During myeloid cell differentiation and activation, key transcription factors including PU.1,
GATA-1, Ikaros, C/EBPα, C/EBPβ and Blimp-1 are shown to play important roles in mediating
cell development and function (75). Blimp-1 has more recently been shown to regulate
differentiation of myeloid cells to macrophages (76). The alteration of Blimp-1 expression
during myeloid differentiation was demonstrated by the observation that Blimp-1 is induced
during M-CSF-driven differentiation of murine myeloid progenitors, and is rapidly expressed
following PMA stimulation of human myeloid cell lines (47,62,77). Blimp-1 regulates key
differentiation genes including c-myc (78), CIITA (49), Spi-B, Id3 (64); and Pax5 (63). These
results support a model that places Blimp-1 at the center of the transcriptional network that
controls cellular terminal differentiation and activation. Consistent with findings that Blimp-1
is involved in recruiting factors that directly modify histones to cause gene silencing (42), we
find an inverse correlation between enhanced Blimp-1 binding to the NLRP12 promoter and a
decrease in H3 acetylation that is associated with gene transcription.
In addition to Blimp-1, it is necessary to evoke another unknown molecule(s) or mechanism
(s) for a more complete inhibition of NLRP12 expression during myeloid treatment. While
PMA-induced myeloid differentiation resulted in a near-complete depletion of NLPR12
expression, Blimp-1 only partially inhibited NLRP12 promoter activity in a cell line and
Blimp-1 gene deletion only partially rescued Nlrp12 expression in differentiating murine
mononuclear cells. Future identification of this second inhibitor will be important to fully
understand how NLRP12 is regulated.
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In summary, we propose that the transcriptional silencing of the NLRP12 gene, a negative
regulator of inflammatory gene induction, is essential for the development of a proper immune
response. NLRP12 gene silencing is mediated by Blimp-1 during both innate immune
activation and cellular differentiation. This work is the first to link the transcriptional repressor,
Blimp-1, to NLR gene silencing during TLR activation and myeloid differentiation.
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NLRP12 expression is regulated by specific TLRs. (A) Human primary granulocytes were
stimulated with the indicated TLR agonists for 1 hour. NLRP12 expression was analyzed by
qPCR analysis of total RNA. NLRP12 expression was normalized to the housekeeping gene
β-glucuronidase (GusB). Data are an average of three separate experiments. (B) TLR3 and
TLR5 expression in total human peripheral blood cells, granulocyte isolated from human
peripheral blood cells by ficoll separation, and in the HEK293T cell line were assessed by
qPCR. TLR expression was normalized to the expression of GusB. (C) NLRP12 expression in
human adherent peripheral blood cells stimulated for 1, 6, 8 and 16 hours with phenol-purified
LPS (TLR4 agonist). NLRP12 expression was normalized to the expression of 18S rRNA and
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represented as fold difference compared to control. Error bars represent the SEM of three
separate cell preparations and experiments. (D) The reduction of nuclear verses cytoplasmic
NLRP12 expression after TLR activation. U937 cells were stimulated with 500 ng/ml LPS for
3, 5, 8, 18 and 24 hours followed by isolation of nuclear verses cytoplasmic mRNA as described
in materials and methods. NLRP12 mRNA abundance was then quantified by qPCR and
normalized to GusB. (E) The stability of the NLRP12 mRNA is similar in cells treated with a
transcriptional inhibitor or stimulated with LPS. The human pre-monocyte cell line HL-60 was
treated with 1.25% DMSO for 3 days to induce differentiation into NLRP12 expressing
neutrophils. Differentiated HL-60 cells were then stimulated with LPS (squares), treated with
DRB (triangles), treated with DRB plus stimulated with LPS, or exposed to 0.1% DMSO
(circles) as a vehicle control for 0, 1, 2, 3, and 4 hours. NLRP12 mRNA abundance was then
quantified by qPCR. The amount of NLRP12 mRNA at the time before DRB addition (0 hr)
was set to 1, and the amount remaining at the indicated time points was determined. Error bars
represent the SEM of five separate experiments.
Lord et al. Page 18














The NLRP12 promoter contains a potential Blimp-1 binding site. (A) Sequence of the human
NLRP12 promoter region from − 399 to +223 bp. Several transcription factor DNA binding
sites are shown. The DNA binding site for Blimp-1 is underlined. The transcriptional start site
is denoted by an arrow (+1), and the ATG of the translational start site is underlined. (B)
Comparison of the putative Blimp-1 binding site in the NLRP12 promoter with the Blimp-1
DNA binding sequences of the ten other Blimp-1 targets (boxed). (C). U937 human monocyte
cells were stimulated with LPS for 0, 2, 4, 8 and 24 hours. NLRP12 protein was detected by
immunoprecipitation followed by immunoblot with two different NLRP12 antibodies as
described. Blimp-1 protein expression was assessed by immunoblot. Immunoblot with anti-
GAPDH indicates equal protein loading. (D). U937 cells were differentiated with PMA for 0,
2, 4, 8 and 24 hours and analyzed as in (C). Shown is a representative blot of three separate
experiments.
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Blimp-1 binds to the putative Blimp-1 binding site in the human NLRP12 promoter and is
regulated by PMA and TLR stimulation. (A) EMSA analysis of Blimp-1 DNA binding to the
novel site in the NLRP12 promoter. Nuclear extracts were obtained from HEK293T cells
transfected with a pcDNA control or a Flag-Blimp-1 expression vector. EMSA was performed
using the Blimp-1 binding site in the NLRP12 promoter. Binding was competed with increasing
concentrations of cold probe to indicate specificity. An anti-Flag antibody was used to
supershift the protein-DNA complexes to indicate specificity. A non-specific anti-p65 antibody
was used as a control. A representative of three separate experiments is shown. (B). Nuclear
extracts from U937 cells stimulated with PMA and LPS for 24 hours were used in a DAPA
Lord et al. Page 20













analysis of Blimp-1 binding to the NLRP12 promoter. DAPAs were performed by incubating
U937 nuclear extracts with an immobilized, biotinylated double-stranded oligo corresponding
to the potential Blimp-1 binding site in the NLRP12 promoter. Bound protein complexes were
washed, eluted with sample buffer and subjected to SDS-PAGE and Western blot analysis with
a Blimp-1-specific antibody. A representative DAPA of two separate experiments is shown.
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The NLRP12 promoter is downregulated by LPS stimulation and Blimp-1 expression in human
monocyte cells. (A). Schematic representation of luciferase reporter constructs generated to
assess NLRP12 promoter luciferase activity. For promoter analysis, 1412 bp of the NLRP12
promoter was inserted into pGL3-luciferase to drive luciferase reporter expression (NLRP12-
luc). A mutant NLRP12 promoter luciferase reporter was generated by mutating 4 bp located
in the putative Blimp-1 binding site (mutNLRP12-luc). Deletions of the NLRP12 promoter
were also cloned into pGL4.10-luciferase vector including a 399 bp fragment (pGL4-399), a
852 bp fragment (pGL4-852), and the full length 1412 fragment (pGL4-1412). (B). The U937
human monocyte cell line was transfected with the pGL3-Control vector, Mon-1 luc, or
mutMon-1 luc. After transfection, cells were either left unstimulated, stimulated with LPS or
transfected with a Flag-tagged Blimp-1 expression vector. Twenty-four hours later, cells were
lysed and luciferase levels were determined as described in Materials and Methods. Error bars
represent the SEM of four separate experiments. (C). The U937 human monocyte cell line was
transfected with the pGL3-Control vector, NLRP12-luc, pGL4.10-luciferase vector,
pGL4-399, pGL4-852 and pGL4-1412. After transfection, cells were either left unstimulated,
stimulated with LPS or transfected with a Flag-tagged Blimp-1 expression vector. Twenty-
four hours later, cells were lysed and luciferase levels were determined as described in
Materials and Methods. Error bars represent the SEM of three separate experiments.
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Blimp-1 is recruited to the NLRP12 promoter after TLR stimulation in vivo. (A) Human U937
cells were stimulated with LPS for 8 hours followed by CHIP using a control IgG antibody,
an antibody to acetylated Histone3, and an antibody to Blimp-1. DNA was eluted from the
CHIP and subjected to PCR with primers specific for the NLRP12 promoter. PCR products
were analyzed on an agarose gel. Lanes include PCR product obtained from input DNA, a 1/10
dilution of input DNA, immunoprecipitation with an IgG control antibody,
immunoprecipitation with an anti-Blimp-1 antibody, and water as a PCR control. Data are
representative of three separate experiments. (B) Chromatin Immunoprecipitation was
performed to confirm the interaction of Blimp-1 with the NLRP12 promoter in vivo. The human
monocyte cell line U937 was stimulated with LPS for 1, 4 and 8 hours. Chromatin bound
Blimp-1 complexes were immunoprecipitated using an anti-Blimp-1 antibody followed by
analysis of complexed chromatin by qPCR using primers specific for the NLRP12 promoter.
qPCR using primers specific for the NQO1 promoter were used as a negative control. qPCR
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values have been normalized to input. Precipitation with an unrelated antibody was used as
negative control. Data are a representative of three separate experiments. (C) Chromatin
Immunoprecipitation was performed to measure acetylated-Histone 3 (H3) levels with the
NLRP12 promoter in vivo. The human monocyte cell line U937 was stimulated with LPS for
1, 4 and 8 hours. Chromatin bound acetylated-H3 complexes were immunoprecipitated using
an anti- acetylated-H3 antibody followed by analysis of complexed chromatin by qPCR using
primers specific for the NLRP12 promoter. qPCR values have been normalized to input. Data
are an average of four experiments.
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Reduced expression of NLRP12 during murine bone marrow differentiation is regulated by
Blimp-1. (A) Murine bone marrow cells were isolated from C57BL/6 mice and differentiated
in vitro with GM-CSF or stimulated with LPS for 3 hrs. Blimp-1 and NLRP12 expression were
assessed by qPCR analysis of RNA isolated at the indicated time points. Data are a
representative of three separate experiments. (B) Murine bone marrow cells were isolated from
control ER+/+prdm1F/F mice or from ERCre/+prdm1F/F (48) mice in which Blimp-1
expression is knocked out under the control of the ER promoter . Bone marrow cells were
differentiated in vitro with GM-CSF. NLRP12 expression was assessed by qPCR analysis of
RNA isolated at the indicated time points. Data are an average of at least three separate
experiments and error bars are calculated using SEM values.
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